ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0117

Diagnostic Utility of Renal Hypertrophy on CT Imaging for Differentiating Acute Interstitial Nephritis from Other Causes of AKI

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Tanabe, Jun, Sei Marianna Ika Daigaku, Kawasaki, Kanagawa Prefecture, Japan
  • Yazawa, Masahiko, Sei Marianna Ika Daigaku, Kawasaki, Kanagawa Prefecture, Japan
  • Ogata, Masatomo, Sei Marianna Ika Daigaku, Kawasaki, Kanagawa Prefecture, Japan
  • Shibagaki, Yugo, Sei Marianna Ika Daigaku, Kawasaki, Kanagawa Prefecture, Japan
Background

Early treatment of acute interstitial nephritis (AIN) is effective; however, kidney biopsy, the gold standard for diagnosis, is often unfeasible in critically ill patients. Although kidney hypertrophy is a well-recognized feature of AIN, its diagnostic utility remains unclear. We evaluated CT-based kidney hypertrophy as a non-invasive AIN predictor.

Methods

We retrospectively analyzed 40 adults who undergoing kidney biopsy for AKI (2010-2024) with pre- and post-AKI CT scans (AIN=16; non-AIN=24). Kidney hypertrophy rate was defined as the percentage increase in kidney volume. We evaluated five predictors: the classic triad, urinary white blood cells >10/high-power field, peripheral eosinophils >500/μL, drug exposure (antibiotics, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors), and kidney hypertrophy >20%. A logistic regression model and weighted diagnostic score were constructed, and discrimination was assessed using the area under the receiver operating characteristic curve (AUC).

Results

There was no significant difference in age (67.7 vs. 65.6 years) or estimated glomerular filtration rate (26.8 vs. 23.7 mL/min/1.73 m2) between the groups. The AIN group had higher eosinophils (477 vs. 153/µL, P = 0.02), triad positivity (56% vs. 25%, P=0.046), and kidney hypertrophy (140.0 vs. 108.8 %, P < 0.01). Stepwise variables inclusion increased the AUC to 0.85 with all five predictors. A scoring system (range 0–4.5; triad 0.5, eosinophils 1, drug exposure 1, hypertrophy 2) showed good discrimination. At a cutoff of 2.5, sensitivity was 75.0%, specificity 79.2%, positive predictive value (PPV) 70.6%, and negative predictive value 82.6%. A score ≥4.0 yielded 100% specificity and PPV (Figure).

Conclusion

Kidney hypertrophy rate was 40% in AIN patients. A combined clinical-imaging score showed good discrimination, potentially aiding early diagnosis when biopsy is unfeasible.

Digital Object Identifier (DOI)